Editas Medicine Announces Pricing of Up to $319.4 Million Public Offering

Editas Medicine (Nasdaq: EDIT) priced an underwritten public offering of 55,555,556 common shares plus accompanying warrants to purchase 55,555,556 shares at a combined price of $2.25 per unit, for expected gross proceeds of about $125 million before expenses.

Rhea-AI Summary

Editas Medicine (Nasdaq: EDIT) priced an underwritten public offering of 55,555,556 common shares plus accompanying warrants to purchase 55,555,556 shares at a combined price of $2.25 per unit, for expected gross proceeds of about $125 million before expenses.

The common stock warrants are immediately exercisable at $3.50 per share (or $3.4999 for pre-funded warrants) and could generate up to an additional $194.4 million in gross proceeds if fully exercised. The offering, sold entirely by Editas Medicine, is expected to close on or about May 27, 2026, subject to customary conditions.

Positive

• Primary gross proceeds of approximately $125 million before fees and expenses
• Additional potential gross proceeds of about $194.4 million from full warrant exercise
• Warrants are immediately exercisable at $3.50 per share
• Offering conducted under an effective Form S-3 shelf registration

Negative

• Issuance of 55,555,556 new common shares, creating shareholder dilution
• Warrants for up to 55,555,556 additional shares may add further dilution if exercised

Argus May 26 session

+11.59% close to close Open Argus

Details

News Market Reaction – EDIT

On May 26, the day this news came out, EDIT closed 11.59% above the previous close.

Data tracked by StockTitan Argus for the May 26 session.

Key Figures

Shares offered: 55,555,556 shares Warrants offered: 55,555,556 warrants Offering price: $2.25 +5 more

Shares offered

55,555,556 shares

Common stock in underwritten public offering

Warrants offered

55,555,556 warrants

Common stock warrants accompanying offered shares

Offering price

$2.25

Combined public offering price per share plus accompanying warrant

Gross proceeds (shares)

$125.0 million

Expected aggregate gross proceeds, excluding warrant exercise

Additional warrant proceeds

$194.4 million

Potential additional gross proceeds if all warrants exercised

Warrant exercise price

$3.50 per share

Exercise price for common stock warrants

Prefunded warrant exercise price

$3.4999 per prefunded warrant

Exercise price if exercised for pre-funded warrants

Prefunded strike

$0.0001 per share

Exercise price of any pre-funded warrants issued

Historical Context

5 past events · Latest: May 14

5 events

1. May 14

   Preclinical data update

   24h Move

   -1.7%

   New EDIT-401 preclinical hyperlipidemia data at ASGCT and TIDES meetings.

2. May 05

   Earnings and pipeline

   24h Move

   +1.3%

   Q1 2026 results with EDIT-401 progress and cash runway into Q3 2027.

3. Apr 27

   Conference plans

   24h Move

   +5.9%

   Announcement of multiple upcoming conferences featuring EDIT-401 data.

4. Mar 27

   Patent decision

   24h Move

   -3.9%

   USPTO reaffirmed PTAB decision favoring Broad on CRISPR/Cas9 inventorship.

5. Mar 09

   Earnings and outlook

   24h Move

   +16.0%

   Q4 2025 results, EDIT-401 timelines, and cash runway into Q3 2027.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

underwritten public offering, common stock warrants, pre-funded warrants, exercise price, +4 more

8 terms

underwritten public offering financial

"today announced the pricing of an underwritten public offering of 55,555,556 shares"

An underwritten public offering is when a company sells new shares of its stock to the public with the help of a financial firm, called an underwriter. The underwriter agrees to buy all the shares upfront, reducing the company's risk, and then sells them to investors. This process helps companies raise money quickly and confidently from a wide range of buyers.

common stock warrants financial

"and accompanying common stock warrants to purchase an aggregate of 55,555,556 shares"

Common stock warrants are tradable certificates that give the holder the right, but not the obligation, to buy a company’s common shares at a fixed price before a specified expiration date. They work like long-term options issued by the company and can provide cheaper, leveraged exposure to a stock’s potential upside; however, if holders use the warrants to buy shares, the total number of shares increases, which can dilute the value of existing shares.

pre-funded warrants financial

"shares of common stock (or pre-funded warrants in lieu thereof)"

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

exercise price financial

"will have an exercise price of $3.50 per share (or $3.4999 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

prospectus supplement regulatory

"The offering is being made only by means of a prospectus supplement and accompanying prospectus"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

shelf registration statement regulatory

"pursuant to an effective shelf registration statement on Form S-3 (File No. 333-277471)"

A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.

form s-3 regulatory

"shelf registration statement on Form S-3 (File No. 333-277471) that was filed"

Form S-3 is a legal document companies use to register their stock sales with the government, making it easier and faster for them to raise money by selling shares to investors. It’s like having a pre-approved shopping list that lets a company quickly sell new shares when they need funds, without going through a lengthy approval process each time.

registration statement regulatory

"that form a part of the registration statement"

A registration statement is a formal document that companies file with a government agency to offer new shares of stock to the public. It provides essential information about the company's finances, operations, and risks, helping investors make informed decisions. Think of it as a detailed product description that ensures transparency and trust before buying into a company.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, today announced the pricing of an underwritten public offering of 55,555,556 shares of its common stock and accompanying common stock warrants to purchase an aggregate of 55,555,556 shares of common stock (or pre-funded warrants in lieu thereof). Each share of common stock and accompanying common stock warrant are being sold together at a combined public offering price of $2.25. The aggregate gross proceeds from the offering are expected to be approximately $125.0 million (assuming no exercise of the common stock warrants), before deducting underwriting discounts and commissions and offering expenses. If all of the common stock warrants are exercised at their exercise price, the Company would receive additional gross proceeds from the offering of approximately $194.4 million before deducting underwriting discounts and commissions and offering expenses.

Each common stock warrant will be exercisable for shares of common stock (or pre-funded warrants in lieu thereof), will have an exercise price of $3.50 per share (or $3.4999 per share if exercised for pre-funded warrants), will be exercisable immediately and will expire on the earlier of (i) the date that is thirty (30) days following the first public announcement by the Company of Phase 1 clinical data for the Company’s product candidate, EDIT-401, that discloses at least three patients in the trial that each demonstrated greater than 80% reduction in LDL-cholesterol as compared to baseline with at least one (1) month of follow-up and (ii) three years from the date of issuance. Any pre-funded warrants issued upon the exercise of common stock warrants will have an exercise price of $0.0001 per share of common stock, will be immediately exercisable and will expire on the date the pre-funded warrant is exercised in full.

All of the securities in the offering are being sold by Editas Medicine. The offering is expected to close on or about May 27, 2026, subject to satisfaction of customary closing conditions.

Cantor and Wells Fargo Securities are acting as joint book-running managers for the offering.

The securities are being offered pursuant to an effective shelf registration statement on Form S-3 (File No. 333-277471) that was filed with the Securities and Exchange Commission (SEC) on February 28, 2024, as amended by Post-Effective Amendment No. 1 to Form S-3 Registration Statement and Post-Effective Amendment No. 2 to Form S-3 Registration Statement, each filed with the SEC on March 5, 2025, and declared effective on March 21, 2025. The offering is being made only by means of a prospectus supplement and accompanying prospectus that form a part of the registration statement. A preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the offering have been filed with the SEC and are available at www.sec.gov. A final prospectus supplement relating to the offering will be filed with the SEC and will be available for free on the SEC’s website at www.sec.gov. Copies of the final prospectus supplement may be obtained, when available, by contacting Cantor Fitzgerald & Co., Attention: Capital Markets, 110 East 59th Street, 6th Floor New York, New York 10022, Email: prospectus@cantor.com; or Wells Fargo Securities, LLC, Attention: Equity Syndicate Department, 90 South 7th Street, 5th Floor, Minneapolis, Minnesota 55402, at (800) 645-3751 (option #5) or email a request to WFScustomerservice@wellsfargo.com.

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Editas Medicine
As a pioneering gene editing company, Editas Medicine is focused on translating the power and potential of CRISPR genome editing systems into a robust pipeline of transformative in vivo medicines for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize durable, precision in vivo gene editing medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute’s Cas12a patent estate and Broad Institute and Harvard University’s Cas9 patent estates for human medicines.

Forward-Looking Statements
This press release contains forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995, including statements about the anticipated closing of the offering. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: the satisfaction of customary closing conditions related to the public offering and the impact of general economic, industry or political conditions in the United States or internationally. These and other risks are described in greater detail under the captions “Risk Factor Summary” and “Risk Factors” included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed with the SEC on March 9, 2026 and in the Company’s subsequent filings with the SEC, the Company’s preliminary prospectus supplement filed with the SEC on May 26, 2026, and other filings the Company may make with the SEC in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor and Media Contacts:
ir@editasmed.com
media@editasmed.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Editas Medicine (EDIT) announce about its May 2026 stock offering?

Editas Medicine announced pricing of an underwritten public offering of 55,555,556 common shares with accompanying warrants, targeting about $125 million in gross proceeds before fees. According to Editas Medicine, all securities in this offering are being sold by the company.

How much capital could Editas Medicine (EDIT) raise from the May 2026 offering?

Editas Medicine expects about $125 million in gross proceeds from the base offering, before discounts and expenses. According to Editas Medicine, full exercise of the common stock warrants could provide up to an additional $194.4 million in gross proceeds.

What are the pricing terms of the Editas Medicine (EDIT) May 2026 stock and warrant offering?

Each Editas Medicine common share and accompanying common stock warrant is priced at a combined $2.25. According to Editas Medicine, each warrant is immediately exercisable at $3.50 per share, or $3.4999 when exercised for pre-funded warrants in lieu of common stock.

When do the Editas Medicine (EDIT) common stock warrants from the May 2026 offering expire?

The Editas warrants expire on the earlier of three years from issuance or 30 days after specified EDIT-401 Phase 1 data are publicly announced. According to Editas Medicine, the trigger requires at least three patients with over 80% LDL-cholesterol reduction and one month follow-up.

When is the Editas Medicine (EDIT) May 2026 public offering expected to close?

The Editas Medicine underwritten public offering is expected to close on or about May 27, 2026. According to Editas Medicine, completion of the transaction remains subject to satisfaction of customary closing conditions typically required for offerings of this type.

How are pre-funded warrants structured in the Editas Medicine (EDIT) May 2026 offering?

Pre-funded warrants may be issued instead of common shares upon warrant exercise and have a $0.0001 per-share exercise price. According to Editas Medicine, these pre-funded warrants are immediately exercisable and expire when they have been exercised in full for common stock.

What regulatory filings support the Editas Medicine (EDIT) May 2026 stock and warrant sale?

The Editas offering uses an effective shelf registration statement on Form S-3, file number 333-277471. According to Editas Medicine, related amendments were filed in March 2025, and the registration statement was declared effective on March 21, 2025.